Trial Profile
Analysis of Crushed and Whole Tablet Genvoya
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 01 Jan 2023 Results published in the AIDS Research and Human Retroviruses
- 16 Feb 2022 Primary endpoint has not been met (Cmax of TAF in plasma after single doses of whole tablet and crushed tablet of this fixed dose antiretroviral combination), as per as per Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 16 Feb 2022 Primary endpoint has not been met, (Cmax of TVF in plasma after single doses of whole tablet and crushed tablet of this fixed dose antiretroviral combination), as per Results presented at the 29th Conference on Retroviruses and Opportunistic Infections